Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$227.6MCash on Hand
60.6mo Cash Runway
Follow CLYM by emailGet an email when CLYM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLYM, unsubscribe in one click. Privacy
📣 What CLYM Says Is Next
in 2027 · “Anticipate initial SC data in 2027.”
Company press release, Nov 5, 2026 · SEC filing
in 2027 · “Anticipate additional data from both ongoing studies in 2027.”
Company press release, Nov 5, 2026 · SEC filing
in 2027 · Budoprutug: “Enrollment is ongoing in the third cohort (1000 mg), additional data from all cohorts, including longer-term follow-up, expected in 2027.”
Company press release, Nov 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: $227.6M cash as of Sept 30, runway into H2 2028; R&D $11.0M vs $9.1M; G&A $5.8M. Also presented CLYM116 Phase 1 data showing >90% free APRIL suppression at 12 weeks and budoprutug Phase 2 PrisMN 200 mg data. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing Climb Bio filed a universal shelf registration statement on Form S-3ASR allowing it to sell, from time to time, an indeterminate amount of debt securities, common stock, preferred stock, subscription rights, units and warrants. Specific offering terms will be set out in later prospectus supplements. Form S-3ASR · SEC filing
Oct 26, 2026 ·
Clinical trial Presented initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week. At 200 mg, mean PLA2R antibody reduction was 70% at Week 12 and 5 of 13 patients (38%) reached immunologic remission. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Climb Bio and Mabworks reported additional Phase 1 healthy volunteer data for CLYM116/MIL116 at ASN Kidney Week: ~33-day half-life, ≥90% free APRIL suppression through 12 weeks at doses ≥480 mg, and ~70% Gd-IgA1 and ~60% IgA reduction at 12 weeks after 800 mg. NAVIGATE-2 Phase 2 data expected 1H 2027. Form 8-K · SEC filing · Press release
Sep 3, 2026 ·
Clinical trial Reported positive initial Phase 1 data for CLYM116, an anti-APRIL antibody for IgA nephropathy, with a ~29-day projected half-life and >90% free APRIL suppression after a single 320 mg dose. IgA and Gd-IgA1 suppression of ~60-75% was maintained through 12 weeks, with no serious adverse events. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Clinical trial Beijing Mabworks Biotech announced on August 13, 2026 that it dosed the first patient with immunoglobulin A nephropathy in a Phase 2 trial in China, conducted in collaboration with Climb Bio. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1 · Recruiting · A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) Registry primary completion date, not a results date
Aug 2027 · Phase 1/2 · Recruiting · A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) Registry primary completion date, not a results date
Sep 2027 · Phase 1/2 · Recruiting · A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) Registry primary completion date, not a results date
Oct 2027 · Phase 2 · Recruiting · A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CLYM holds $227.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.3M/quarter from operations,
an estimated runway of 60.6 months at that rate (BioRadar estimate, not company guidance).
Share count 58,738,178 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CLYM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLYM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.